IL-17 Inhibition: Emerging Perspectives in the Future Management of Axial Spondyloarthritis

Chairperson:

Atul Deodhar¹

Speakers:

Dirk Elewaut,² Dominique Baeten,³ Xenofon Baraliakos⁴

1. Oregon Health and Science University, Portland, Oregon, USA 
2. Ghent University Hospital, Ghent, Belgium 
3. Clinical Immunology and Rheumatology Academic Medical Center/ University of Amsterdam, Amsterdam, Netherlands 
4. Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany

Disclosure:

Atul Deodhar has participated in advisory boards and received research grants from AbbVie, Amgen, Janssen, Novartis, Pfizer, and UCB. Dirk Elewaut has received a research grant, consultation fees, and speaker honoraria from AbbVie, Boehringer Ingelheim, BMS, and Merck. Dominique Baeten has received consultation fees from AbbVie, Pfizer, MSD, UCB, Janssen, Novartis, Eli Lilly, Boehringer Ingelheim, BMS, Roche, Glenmark, and Zymetech; speaker honoraria from AbbVie, Janssen, MSD, Pfizer, UCB, BMS, and Novartis; and research grants from Pfizer, MSD, UCB, Boehringer Ingelheim, and Janssen. Xenofon Baraliakos has worked as a consultant and received speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Centocor, Chugai, Janssen Biologics, Novartis, Pfizer, Sandoz, UCB, and Werfen.

Acknowledgements:

Writing assistance was provided by Dr Ana Rodríguez de Ledesma, apothecom scopemedical Ltd.

Support:

The symposium was jointly organised and funded by Novartis Pharmaceuticals. All authors received honoraria for preparation and delivery of their presentations. The publication of this article was funded by Novartis Pharmaceuticals. The views and opinions expressed are those of the authors and not necessarily those of Novartis Pharmaceuticals.

Citation:

EMJ Rheumatol. 2015;2[1]:46-54. DOI/10.33590/emjrheumatol/10311245. https://doi.org/10.33590/emjrheumatol/10311245.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.